Climb Bio reports positive CLYM116 Phase 1 data: ~29-day half-life, >90% APRIL suppression, Q12W dosing support

Climb Bio, Inc.

CLYM116 half-life ~29 days, 3x longer than sibeprenlimab; >90% free APRIL suppression after single 320 mg dose.
Single 320 mg dose drove 60-75% suppression of IgA, Gd-IgA1, and IgM, maintained through 12 weeks.
No serious adverse events, dose-limiting toxicities, or hypogammaglobulinemia in 46-subject Phase 1 trial.
Phase 2 NAVIGATE-2 (800 mg load, 400 mg Q8W/Q12W) ongoing; initial data expected H1 2027; Phase 3 initiation in 2027.
High-concentration 200 mg/mL formulation enables 400 mg single SC injection; pre-filled syringe complete; autoinjector in development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.